和元生物：2025年半年度净利润约-1.05亿元

Core Viewpoint - The company reported a slight increase in revenue for the first half of 2025, but continued to face significant net losses [2] Financial Performance - The company's revenue for the first half of 2025 was approximately 120 million, representing a year-on-year increase of 6.01% [2] - The net loss attributable to shareholders for the same period was approximately 105 million [2] - Basic earnings per share for the first half of 2025 were a loss of 0.163 [2] - In comparison, the revenue for the same period in 2024 was approximately 113 million, with a net loss of about 113 million and a basic earnings per share loss of 0.175 [2]